在帕金森病中,USP14缺乏通过调节S100A8/A9来消除α-synuclein
Liuyan Ding1, Lin Lu1, Shaohui Zheng2
1Department of Neurology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Cellular and molecular life sciences : CMLS
|May 23, 2024
概括
在帕金森氏症患者中降低了泛胺特异蛋白酶14 (USP14) 水平.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 遗传学 遗传学 是一个
背景情况:
- 乌比奎丁-蛋白酶体系统的功能障碍与帕金森病 (PD) 中的α-synuclein聚合有关.
- 双化酶 (DUB) 在α-synuclein病理学中的特定作用尚未完全理解.
- 在PD患者的脑脊液 (CSF) 中发现,尤为女性患者的乌比奎丁特异性蛋白酶14 (USP14) 水平下降.
研究的目的:
- 为了研究USP14和帕金森病的α-synuclein病理之间的关系.
- 在PD模型中探索针对USP14的治疗潜力.
主要方法:
- 对PD患者的CSF中USP14水平的分析.
- 产生USP14异构小鼠,与PD转基因模型交叉或注射携带人类α-synuclein的腺相关病毒 (AAV).
- 在小鼠模型中评估行为异常,α-synuclein沉积和炎症反应.
- 研究涉及S100A8/A9.9的下游分子机制.
主要成果:
- 在女性PD小鼠模型中,USP14缺乏改善了行为缺陷和α-synuclein病理.
- 在雌性小鼠中,USP14无活化减少了前炎性反应,但在雄性小鼠中产生了相反的效果.
- 在女性模型中,上调的S100A8/A9蛋白被确定为下游目标.
- 通过自和抑制微质炎症S100A8/A9介导的α-synuclein降解.
结论:
- USP14在男性和女性PD病变发生过程中起着不同的作用.
- 通过S100A8/A9的USP14缺乏,为α-synucleinopathies提供了一个潜在的治疗策略.
- USP14代表了帕金森病的新型治疗点,特别是在女性患者中.
关键词:
自自是一种自的过程.帕金森病是帕金森氏症的一种疾病.S100A8 / A9 / A9 / S100A8 / A9 / S100A8 / A9 / S100A8 / A9 / S100A9 / S100A8 / S100A9 / S100A8 / S100A9 / S100A9 / S100A8 / S100A9 / S100A9 / S100A9 / S100A9 / S100A8 / S100A9 / S100A9 / S100A8 / S100A9 / S100A9 / S100A9 / S100A8 / S100A9 / S100A9 / S100A8 / S100A9 / S100A8 / S100A9 / S100A9 / S100A8 / S100A8 / S100A9 / S100A8 / S100A9 / S100A8 / S100A9 / S100A8 / S100A9 / S100A8 / S100A8 / S100A8 / S100A9美国 14 美元α-synuclein 是一种同核蛋白.更多相关视频
12:01Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
10.7K
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
5.9K
相关概念视频
01:37Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:15Parkinson's Disease: Overview
528
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
528
01:24Parkinson's Disease: Treatment
261
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
261